These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8757459)

  • 1. Effect of USP apparatus 1 and 2 at different rotational speeds on dissolution of niacin formulations.
    Kirchhoefer RD; Hamilton JF
    J AOAC Int; 1996; 79(4):1005-8. PubMed ID: 8757459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin. I: Dissolution profiles of sustained-release niacin products by automated and manual procedures.
    Kirchhoefer RD; Hipp S
    J AOAC Int; 1993; 76(2):394-8. PubMed ID: 8471864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations.
    Rohrs BR; Burch-Clark DL; Witt MJ; Stelzer DJ
    J Pharm Sci; 1995 Aug; 84(8):922-6. PubMed ID: 7500274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules.
    Carvalho-Silva B; Moreira-Campos LM; Nunan EA; Vianna-Soares CD; Araujo-Alves BL; Cesar IC; Pianetti GA
    Farmaco; 2004 Nov; 59(11):921-7. PubMed ID: 15544798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III.
    Li J; Yang L; Ferguson SM; Hudson TJ; Watanabe S; Katsuma M; Fix JA
    AAPS PharmSciTech; 2002; 3(4):E33. PubMed ID: 12916927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.
    Poon IO; Chow DS; Liang D
    Am J Health Syst Pharm; 2006 Nov; 63(21):2128-34. PubMed ID: 17057051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation.
    Mendes TC; Simon A; Menezes JCV; Pinto EC; Cabral LM; de Sousa VP
    Chem Pharm Bull (Tokyo); 2019; 67(1):23-31. PubMed ID: 30606948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance.
    Deng G; Ashley AJ; Brown WE; Eaton JW; Hauck WW; Kikwai LC; Liddell MR; Manning RG; Munoz JM; Nithyanandan P; Glasgow MJ; Stippler E; Wahab SZ; Williams RL
    Pharm Res; 2008 May; 25(5):1100-9. PubMed ID: 18172581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro study of six carbamazepine products.
    Mittapalli PK; Suresh B; Hussaini SS; Rao YM; Apte S
    AAPS PharmSciTech; 2008; 9(2):357-65. PubMed ID: 18431676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product.
    Qureshi SA; McGilveray IJ
    Eur J Pharm Sci; 1999 Feb; 7(3):249-58. PubMed ID: 9845813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulating the hydrodynamic conditions in the United States Pharmacopeia paddle dissolution apparatus.
    McCarthy LG; Kosiol C; Healy AM; Bradley G; Sexton JC; Corrigan OI
    AAPS PharmSciTech; 2003; 4(2):E22. PubMed ID: 12916904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP dissolution IV: comparison of methods.
    Carstensen JT; Lai TY; Prasad VK
    J Pharm Sci; 1978 Sep; 67(9):1303-7. PubMed ID: 690839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of BP and USP rotating basket dissolution apparatus.
    Smith WJ; Heaume PE; Hailey DM; Lea AR
    J Pharm Pharmacol; 1985 Feb; 37(2):124-5. PubMed ID: 2858545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules.
    Tan Y; Si X; Zhong L; Feng X; Yang X; Huang M; Wu C
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1669-77. PubMed ID: 27066697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro release of ketoprofen suppositories using the USP basket and the flow-through cell dissolution methods.
    Medina JR; Padilla AR; Hurtado M; Cortés AR; Domínguez-Ramírez AM
    Pak J Pharm Sci; 2014 May; 27(3):453-8. PubMed ID: 24811800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
    Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
    Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
    Strauch S; Jantratid E; Dressman JB
    J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of USP dissolution and drug release standards.
    Cohen JL; Hubert BB; Leeson LJ; Rhodes CT; Robinson JR; Roseman TJ; Shefter E
    Pharm Res; 1990 Oct; 7(10):983-7. PubMed ID: 2281043
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Medina-López R; Guillén-Moedano S; Hurtado M
    ADMET DMPK; 2020; 8(4):411-423. PubMed ID: 35300193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.